Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
ACS Medicinal Chemistry Letters
|
November 17, 2022
Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode
Stacey M Southall, Joydeep Banerjee, Jason Brown, et al.
Nature Communications
|
December 27, 2024
Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
Thomas L Williams, Grégory Verdon, Rhoda E Kuc, et al.
Urologic Oncology
|
June 19, 2026
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio
Devika Nandwana, Jayant Siva, Laura Davis, et al.
British Journal of Pharmacology
|
April 11, 2006
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist
Richard J Wilson, Gerard M P Giblin, Susan Roomans, et al.
Journal of Medicinal Chemistry
|
June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine
Sarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
Journal of Medicinal Chemistry
|
April 16, 2021
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Huikai Sun, Holger Monenschein, Hans H Schiffer, et al.
JMIR Research Protocols
|
May 26, 2020
Effectiveness of Group Cognitive Behavioral Therapy and Exercise in the Management of Major Depressive Disorder: Protocol for a Pilot Randomized Controlled Trial
Mojtaba Yekrang Safakar, Marianne Hrabok, Liana Urichuk, et al.
Plos One
|
February 9, 2010
Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants
David Metzgar, Christopher A Myers, Kevin L Russell, et al.
ACS Chemical Neuroscience
|
March 4, 2022
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes
Andrew D Cansfield, Mark A Ator, Joydeep Banerjee, et al.
Molecular Autism
|
October 26, 2019
Disruption of PHF21A causes syndromic intellectual disability with craniofacial anomalies, epilepsy, hypotonia, and neurobehavioral problems including autism
Hyung-Goo Kim, Jill A Rosenfeld, Daryl A Scott, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
ACS Medicinal Chemistry Letters
|
November 17, 2022
Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode
Stacey M Southall, Joydeep Banerjee, Jason Brown, et al.
Nature Communications
|
December 27, 2024
Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
Thomas L Williams, Grégory Verdon, Rhoda E Kuc, et al.
Urologic Oncology
|
June 19, 2026
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio
Devika Nandwana, Jayant Siva, Laura Davis, et al.
British Journal of Pharmacology
|
April 11, 2006
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist
Richard J Wilson, Gerard M P Giblin, Susan Roomans, et al.
Journal of Medicinal Chemistry
|
June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine
Sarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
Journal of Medicinal Chemistry
|
April 16, 2021
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Huikai Sun, Holger Monenschein, Hans H Schiffer, et al.
JMIR Research Protocols
|
May 26, 2020
Effectiveness of Group Cognitive Behavioral Therapy and Exercise in the Management of Major Depressive Disorder: Protocol for a Pilot Randomized Controlled Trial
Mojtaba Yekrang Safakar, Marianne Hrabok, Liana Urichuk, et al.
Plos One
|
February 9, 2010
Single assay for simultaneous detection and differential identification of human and avian influenza virus types, subtypes, and emergent variants
David Metzgar, Christopher A Myers, Kevin L Russell, et al.
ACS Chemical Neuroscience
|
March 4, 2022
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes
Andrew D Cansfield, Mark A Ator, Joydeep Banerjee, et al.
Molecular Autism
|
October 26, 2019
Disruption of PHF21A causes syndromic intellectual disability with craniofacial anomalies, epilepsy, hypotonia, and neurobehavioral problems including autism
Hyung-Goo Kim, Jill A Rosenfeld, Daryl A Scott, et al.
Page
of 12